Cancer Research and Treatment

Special Articles

The Cancer Clinical Library Database (CCLD) from the Korea-Clinical Data Utilization Network for Research Excellence (K-CURE) Project: Sangwon Lee, Yeon Ho Choi, Hak Min Kim, Min Ah Hong, Phillip Park, In Hae Kwak, Ye Ji Kang, Kui Son Choi, Hyun-Joo Kong, Hyosung Cha, Hyun-Jin Kim, Kwang Sun Ryu, Young Sang Jeon, Hwanhee Kim, Jip Min Jung, Jeong-Soo Im, Heejung Chae; Cancer Res Treat. 2025;57(1):19-27. Published online July 15, 2024; DOI: https://doi.org/10.4143/crt.2024.218

The common data model (CDM) has found widespread application in healthcare studies, but its utilization in cancer research has been limited. This article describes the development and implementation strategy for Cancer Clinical Library Databases (CCLDs), which are standardized cancer-specific databases established under the Korea-Clinical Data Utilization Network for Research Excellence (K-CURE) project by the Korean Ministry of Health and Welfare. Fifteen leading hospitals and fourteen academic associations in Korea are engaged in constructing CCLDs for 10 primary cancer types. For each cancer type-specific CCLD, cancer data experts determine key clinical data items essential for cancer research, standardize these items across cancer types, and create a standardized schema. Comprehensive clinical records covering diagnosis, treatment, and outcomes, with annual updates, are collected for each cancer patient in the target population, and quality control is based on six-sigma standards. To protect patient privacy, CCLDs follow stringent data security guidelines by pseudonymizing personal identification information and operating within a closed analysis environment. Researchers can apply for access to CCLD data through the K-CURE portal, which is subject to Institutional Review Board and Data Review Board approval. The CCLD is considered a pioneering standardized cancer-specific database, significantly representing Korea’s cancer data. It is expected to overcome limitations of previous CDMs and provide a valuable resource for multicenter cancer research in Korea.

Citations

Citations to this article as recorded by

Exploring PIXE Applications in Oncology: A Comprehensive Review
G. J. Naga Raju
International Journal of Advanced Research in Science, Communication and Technology.2025; : 261. CrossRef
Disparities in the Diagnosis and Treatment of Breast Cancer Among People With Disabilities
Hea Lim Choi, Jin-Hyung Jung, Hwa-Young Lee, Kyungdo Han, Dong Wook Shin
JAMA Network Open.2025; 8(11): e2543559. CrossRef
Predictive Mortality and Gastric Cancer Risk Using Clinical and Socio-Economic Data: A Nationwide Multicenter Cohort Study
Seong Uk Kang, Seung-Joo Nam, Oh Beom Kwon, Inhyeok Yim, Tae-Hoon Kim, Na Young Yeo, Myoung Nam Lim, Woo Jin Kim, Sang Won Park
Cancers.2024; 17(1): 30. CrossRef

4,361 View
210 Download
2 Web of Science
3 Crossref

Data Resource Profile: The Cancer Public Library Database in South Korea: Dong-Woo Choi, Min Yeong Guk, Hye Ri Kim, Kwang Sun Ryu, Hyun-Joo Kong, Hyo Soung Cha, Hyun-Jin Kim, Heejung Chae, Young Sang Jeon, Hwanhee Kim, Jipmin Jung, Jeong-Soo Im, Kui Son Choi; Cancer Res Treat. 2024;56(4):1014-1026. Published online April 30, 2024; DOI: https://doi.org/10.4143/crt.2024.207

Abstract PDF Supplementary Material PubReader ePub

This paper provides a comprehensive overview of the Cancer Public Library Database (CPLD), established under the Korean Clinical Data Utilization for Research Excellence project (K-CURE). The CPLD links data from four major population-based public sources: the Korea National Cancer Incidence Database in the Korea Central Cancer Registry, cause-of-death data in Statistics Korea, the National Health Information Database in the National Health Insurance Service, and the National Health Insurance Research Database in the Health Insurance Review & Assessment Service. These databases are linked using an encrypted resident registration number. The CPLD, established in 2022 and updated annually, comprises 1,983,499 men and women newly diagnosed with cancer between 2012 and 2019. It contains data on cancer registration and death, demographics, medical claims, general health checkups, and national cancer screening. The most common cancers among men in the CPLD were stomach (16.1%), lung (14.0%), colorectal (13.3%), prostate (9.6%), and liver (9.3%) cancers. The most common cancers among women were thyroid (20.4%), breast (16.6%), colorectal (9.0%), stomach (7.8%), and lung (6.2%) cancers. Among them, 571,285 died between 2012 and 2020 owing to cancer (89.2%) or other causes (10.8%). Upon approval, the CPLD is accessible to researchers through the K-CURE portal. The CPLD is a unique resource for diverse cancer research to investigate medical use before a cancer diagnosis, during initial diagnosis and treatment, and long-term follow-up. This offers expanded insight into healthcare delivery across the cancer continuum, from screening to end-of-life care.

Citations

Citations to this article as recorded by

Explainable AI for colorectal cancer mortality and risk factor prediction in Korea: A nationwide cancer cohort study
Sang Won Park, Na Young Yeo, Tae-Hoon Kim, Myoung Nam Lim, Inhyeok Yim, Oh Beom Kwon, Seung-Joo Nam, Hui-Young Lee, Woo Jin Kim
International Journal of Medical Informatics.2026; 205: 106125. CrossRef
Trends in the cost of ovarian cancer across phases of care and surgical years in Korea
Byeong-Chan Oh, Sun-Kyeong Park, Sokbom Kang
Journal of Gynecologic Oncology.2026;[Epub] CrossRef
Precision Forecasting in Colorectal Oncology: Predicting Six-Month Survival to Optimize Clinical Decisions
Jaehyuk Lee, Youngchae Cho, Yeunwoong Kyung, Eunchan Kim
Electronics.2025; 14(5): 880. CrossRef
The Impact of Advanced Care Planning on Hospice Utilization in Patients with Cancer: A Nationwide Analysis in Korea
Woorim Kim, Boram Kim, Minju Kim, Jin Young Choi
Cancers.2025; 17(9): 1471. CrossRef
Atrial Fibrillation Risk in Relation to the Clinical Staging of Gastric Cancer: A Nationwide Population-Based Cohort Study
Mi Jin Oh, Yoon Jin Choi, Jin-Hyung Jung, Seunghan Lee, Kyungdo Han, Soo-Jeong Cho
Cancers.2025; 17(12): 2054. CrossRef
Real-world survival outcomes of immune checkpoint inhibitor therapy after standard treatment failure in EGFR-mutated NSCLC: A nationwide cohort study
Jiyeon Lee, Miryoung Kim, Hyun Jin Han, Siin Kim, Hae Sun Suh
Lung Cancer.2025; 206: 108682. CrossRef
Clinical characteristics and survival outcome of vulvar cancer in South Korea: A nationwide study from the Cancer Public Library Database
Chel Hun Choi, Ha kyun Chang, Gi Hwan Bae, Jong Ha Hwang
Journal of Obstetrics and Gynaecology Research.2025;[Epub] CrossRef
Long-term Survival Following Endoscopic Submucosal Dissection Versus Gastrectomy in Early Gastric Cancer Patients Aged 75 Years and Above: A National Retrospective Cohort Study in Korea
Sangwon Lee, Yoon Jin Choi, Bang Wool Eom, Il Ju Choi, Choong-Kun Lee, Jungeun Park, Dong Ah Park, Kui Son Choi
Journal of Gastric Cancer.2025; 25(4): 569. CrossRef
Survival outcomes and treatment patterns in malignant ovarian sex cord-stromal tumors: A population-based analysis
Uisuk Kim, Byeong-Chan Oh, Jaekyung Bae, Sokbom Kang
Gynecologic Oncology.2025; 202: 146. CrossRef
Chronic Obstructive Pulmonary Disease and Inhaled Treatment Effects on Mortality in Patients with Lung Cancer
Jinwoo Lee, Jiyu Sun, Hyun Woo Lee
Annals of the American Thoracic Society.2025; 22(11): 1764. CrossRef
Disparities in the Diagnosis and Treatment of Breast Cancer Among People With Disabilities
Hea Lim Choi, Jin-Hyung Jung, Hwa-Young Lee, Kyungdo Han, Dong Wook Shin
JAMA Network Open.2025; 8(11): e2543559. CrossRef
Prognostic factors in gastric cancer survivors comparing Cox proportional hazards and machine learning using a Korean National cohort
Joonki Lee, Aesun Shin
Discover Oncology.2025;[Epub] CrossRef
Cardiovascular disease risk following radiotherapy among breast cancer survivors: a nationwide cohort study in South Korea
Jeeyoung Lee, Eun Young Park, Won Jin Lee
Breast Cancer Research.2025;[Epub] CrossRef
Risk Factors and Prevention of Stomach Cancer, Excluding Helicobacter pylori
Seung-Woo Lee
The Korean Journal of Helicobacter and Upper Gastrointestinal Research.2024; 24(3): 243. CrossRef
Prediction model for survival of younger patients with breast cancer using the breast cancer public staging database
Ha Ye Jin Kang, Minsam Ko, Kwang Sun Ryu
Scientific Reports.2024;[Epub] CrossRef
Predictive Mortality and Gastric Cancer Risk Using Clinical and Socio-Economic Data: A Nationwide Multicenter Cohort Study
Seong Uk Kang, Seung-Joo Nam, Oh Beom Kwon, Inhyeok Yim, Tae-Hoon Kim, Na Young Yeo, Myoung Nam Lim, Woo Jin Kim, Sang Won Park
Cancers.2024; 17(1): 30. CrossRef

6,670 View
317 Download
12 Web of Science
16 Crossref

Original Articles

General

Establishment of Patient-Derived Organoids Using Ascitic or Pleural Fluid from Cancer Patients: Wonyoung Choi, Yun-Hee Kim, Sang Myung Woo, Yebeen Yu, Mi Rim Lee, Woo Jin Lee, Jung Won Chun, Sung Hoon Sim, Heejung Chae, Hyoeun Shim, Keun Seok Lee, Sun-Young Kong; Cancer Res Treat. 2023;55(4):1077-1086. Published online June 12, 2023; DOI: https://doi.org/10.4143/crt.2022.1630

Abstract PDF Supplementary Material PubReader ePub

Purpose
Patient-derived tumor cells can be a powerful resource for studying pathophysiological mechanisms and developing robust strategies for precision medicine. However, establishing organoids from patient-derived cells is challenging because of limited access to tissue specimens. Therefore, we aimed to establish organoids from malignant ascites and pleural effusions.
Materials and Methods
Ascitic or pleural fluid from pancreatic, gastric, and breast cancer patients was collected and concentrated to culture tumor cells ex vivo. Organoids were considered to be successfully cultured when maintained for five or more passages. Immunohistochemical staining was performed to compare the molecular features, and drug sensitivity was assayed to analyze the clinical responses of original patients.
Results
We collected 70 fluid samples from 58 patients (pancreatic cancer, n=39; gastric cancer, n=21; and breast cancer, n=10). The overall success rate was 40%; however, it differed with types of malignancy, with pancreatic, gastric, and breast cancers showing 48.7%, 33.3%, and 20%, respectively. Cytopathological results significantly differed between successful and failed cases (p=0.014). Immunohistochemical staining of breast cancer organoids showed molecular features identical to those of tumor tissues. In drug sensitivity assays, pancreatic cancer organoids recapitulated the clinical responses of the original patients.
Conclusion
Tumor organoids established from malignant ascites or pleural effusion of pancreatic, gastric, and breast cancers reflect the molecular characteristics and drug sensitivity profiles. Our organoid platform could be used as a testbed for patients with pleural and peritoneal metastases to guide precision oncology and drug discovery.

Citations

Citations to this article as recorded by

The pros and cons of mechanical dissociation and enzymatic digestion in patient-derived organoid cultures for solid tumor
Jing Ren, Mengli Liu, Mingjie Rong, Xuan Zhang, Gang Wang, Yihan Liu, Haijun Li, Shichao Duan
Cell Organoid.2025; 1(1): 9410009. CrossRef
The use of patient-derived xenografts and patient-derived organoids in the search for new therapeutic regimens for pancreatic carcinoma. A review
Emin Gayibov, Tomáš Sychra, Alžběta Spálenková, Pavel Souček, Martin Oliverius
Biomedicine & Pharmacotherapy.2025; 182: 117750. CrossRef
Precision Medicine for Peritoneal Carcinomatosis—Current Advances in Organoid Drug Testing and Clinical Applicability
Harleen Kaur, Josephine A. Wright, Daniel L. Worthley, Elizabeth Murphy, Susan L. Woods
Organoids.2025; 4(1): 2. CrossRef
Three-dimensional models: from cell culture to Patient-Derived Organoid and its application to future liposarcoma research
SAYUMI TAHARA, SYDNEY RENTSCH, FERNANDA COSTAS CASAL DE FARIA, PATRICIA SARCHET, ROMA KARNA, RAPHAEL E. POLLOCK, FEDERICA CALORE
Oncology Research.2025; 33(1): 1. CrossRef
Applications and challenges of patient-derived organoids in hepatobiliary and pancreatic cancers
Jia-Wei Hu, Yan-Zhi Pan, Xiao-Xiao Zhang, Jiang-Tao Li, Yun Jin
World Journal of Gastroenterology.2025;[Epub] CrossRef
Multicenter study correlating molecular characteristics and clinical outcomes of cancer cases with patient-derived organoids
Paloma Navarro, Tatiana P. Grazioso, Arantzazu Barquín, Maria Barba, Mónica Yagüe, Carlos Millán, Irene López, Elena Sevillano, Miguel Quiralte, Paloma Fernández, Diego Losada, Eduardo Caleiras, Julia Calzas, Beatriz Jiménez, Sergio Ruiz-Llorente, Juan Ju
Journal of Experimental & Clinical Cancer Research.2025;[Epub] CrossRef
Patient-derived ovarian cancer models demonstrate the influence of tumor-associated macrophages on therapeutic response
Parisa Nikeghbal, Danielle Burke, Dalet Armijo, Samuel Aldarondo-Quiñones, Diane S. Lidke, Mara P. Steinkamp
OncoImmunology.2025;[Epub] CrossRef
Protocol for generation and utilization of patient-derived organoids from multimodal specimen
Sumin Kang, Mi Rim Lee, Wonyoung Choi, Sun-Young Kong, Yun-Hee Kim
STAR Protocols.2025; 6(3): 104039. CrossRef
Generation of Agarose-Based FFPE Cancer Organoids for Morphology Preservation
Mi Lee, Sumin Kang, A- Jeon, Sung- Choi, Sun- Kong, Yun- Kim
BIO-PROTOCOL.2025;[Epub] CrossRef
Patient-derived organoids in hepatobiliary pancreatic cancer research: Their uses and limitations
Sam Jacobs, William Butterworth, Ewen A Griffiths
World Journal of Gastroenterology.2025;[Epub] CrossRef
Engineering Complexity: Advances in 3D Breast Cancer Models for Precision Oncology
Wonwoo Jeong, Sang Jin Lee
Advanced Healthcare Materials.2025;[Epub] CrossRef
Co-infection of Helicobacter pylori with Epstein-Barr virus in gastric organoids enhances cell proliferation and morphogenesis
Lina Liu, Caixia Zhu, Shuxin Zhang, Yantao Duan, Yulin Zhang, Shujuan Du, Yuping Jia, Fang Wei, Daizhou Zhang, Dazhi Xu, Yuyan Wang, Qiliang Cai, Anna Ruth Cliffe
Journal of Virology.2025;[Epub] CrossRef
Breast cancer organoids: Advancements and applications in precision medicine
Dilys Leung, Jasveena Kaur, Gary Richardson, Thierry Jardé
Critical Reviews in Oncology/Hematology.2025; 214: 104914. CrossRef
Targeting cancer glutamine dependency with a first-in-class inhibitor of the mitochondrial glutamine transporter SLC1A5_var
Yulseung Sung, Ya Chun Yu, Mirim Lee, Seonghun Lim, Yechan Lee, Mincheol Kang, Doru Kwon, Apeksha Parajulee, Junjeong Choi, Do Sik Min, Kuglae Kim, Wan Namkung, Yun-Hee Kim, Sang Myung Woo, Nam Doo Kim, Hee Chan Yoo, Jung Min Han
Nature Communications.2025;[Epub] CrossRef
A novel malignant mesothelioma organoids-T cell co-culture platform for personalized immunochemotherapy testing
Yang Liu, Yang Yang, Songlin An, Hua Wan, Minghao Zhang, Ruihong Yin, Weiting Zhao, Li Huang, Yunshan Zhao, Chenggang Li
Scientific Reports.2025;[Epub] CrossRef
PRMT1 promotes pancreatic cancer development and resistance to chemotherapy
Bomin Ku, David Eisenbarth, Seonguk Baek, Tae-Keun Jeong, Ju-Gyeong Kang, Daehee Hwang, Myung-Giun Noh, Chan Choi, Sungwoo Choi, Taejun Seol, Hail Kim, Yun-Hee Kim, Sang Myung Woo, Sun-Young Kong, Dae-Sik Lim
Cell Reports Medicine.2024; 5(3): 101461. CrossRef
Establishment and Advancement of Pancreatic Organoids
Dong Hyeon Lee
Keimyung Medical Journal.2024; 43(1): 3. CrossRef
Organoid as a promising tool for primary liver cancer research: a comprehensive review
Xuekai Hu, Jiayun Wei, Pinyan Liu, Qiuxia Zheng, Yue Zhang, Qichen Zhang, Jia Yao, Jingman Ni
Cell & Bioscience.2024;[Epub] CrossRef
The use of organoids in creating immune microenvironments and treating gynecological tumors
Ling-Feng Zhou, Hui-Yan Liao, Yang Han, Yang Zhao
Journal of Translational Medicine.2024;[Epub] CrossRef
Organoid: Bridging the gap between basic research and clinical practice
Guihu Weng, Jinxin Tao, Yueze Liu, Jiangdong Qiu, Dan Su, Ruobing Wang, Wenhao Luo, Taiping Zhang
Cancer Letters.2023; 572: 216353. CrossRef

9,306 View
561 Download
17 Web of Science
20 Crossref

Breast cancer

Androgen Receptor as a Predictive Marker for Pathologic Complete Response in Hormone Receptor–Positive and HER-2–Negative Breast Cancer with Neoadjuvant Chemotherapy: Eun-Gyeong Lee, Dong-Eun Lee, Hyun hee Kim, Jai Hong Han, Seeyoun Lee, Han-Sung Kang, Eun Sook Lee, Heejung Chae, Sung Hoon Sim, Keun Seok Lee, Youngmee Kwon, So-Youn Jung; Cancer Res Treat. 2023;55(2):542-550. Published online September 8, 2022; DOI: https://doi.org/10.4143/crt.2022.834

Abstract PDF Supplementary Material PubReader ePub

Purpose
This study investigated pathological complete response (pCR) according to androgen receptor (AR) in breast cancer patients undergoing neoadjuvant chemotherapy and estimated the relationship between AR expression and clinicopathological factors.
Materials and Methods
We identified 624 breast cancer patients who underwent surgery after neoadjuvant chemotherapy at the National Cancer Center in Goyang, Korea from April 2016 to October 2019. We retrospectively collected the clinicopathologic information and AR expression results and analyzed the data according to cancer stage, hormonal receptor (HR) status, human epidermal growth factor receptor 2 (HER2) status, tumor subtype, and pCR.
Results
Among the 624 breast cancer patients, 529 (84.8%) were AR-positive (AR+) patients and 95 (15.2%) were AR-negative (AR–) patients. AR+ patients showed more estrogen receptor (ER) positivity, progesterone receptor (PR) positivity, HER2-positivity, and HR-positive and HER2-negative (HR+/HER2–) subtype. The rate of pCR was 31.4% (196/624). AR– patients had a significantly higher rate of pCR than AR+ patients (AR– 43.2% vs. AR+ 29.3%, p=0.007). The tumor factors associated with pCR were early stage, histologic grade 3, ER-negative, PR-negative, AR-negative, HER2-positive, and high Ki-67 values. In univariable analysis, AR+ significantly decreased the state of pCR (odds ratio, 0.546; 95% confidence interval, 0.349 to 0.853; p=0.008). According to tumor subtype, AR– tumor showed higher pCR rate in HR+/HER2– subtype (AR– 28.6% vs. AR+ 7.3%, p=0.022).
Conclusion
AR expression is predominant in the HR+/HER2– subtype. AR– is significantly associated with the pCR rate in breast cancer patients, especially within HR+/HER2– subtype. When determining neoadjuvant chemotherapy for the HR+/HER2– subtype, AR expression can be considered as a pCR predictive marker.

Citations

Citations to this article as recorded by

The prevalence and clinical significance of residual occult breast cancer after neoadjuvant chemotherapy: reassessing surgical pathology in cases initially described as pathological complete response
Di Ai, Eliel N Arrey, Lauren M Postlewait, Yuan Gao, Xiaoxian Li
Histopathology.2025; 86(7): 1112. CrossRef
Androgen Receptor Positivity in Non-Metastatic Breast Cancer Patients and Its Prognostic Implications—A Retrospective Study
Rexeena Bhargavan, Anitha Mathews, Lakshmi Subhadradevi, Jagathnath K. M. Krishna, Kurian Cherian, Paul Augustine
Indian Journal of Surgical Oncology.2025;[Epub] CrossRef
Neo-adjuvant therapies for ER positive/HER2 negative breast cancers: from chemotherapy to hormonal therapy, CDK inhibitors, and beyond
Athina Stravodimou, Ioannis A. Voutsadakis
Expert Review of Anticancer Therapy.2024; 24(3-4): 117. CrossRef
Luminal androgen receptor subtype and tumor-infiltrating lymphocytes groups based on triple-negative breast cancer molecular subclassification
Miseon Lee, Tae-Kyung Yoo, Byung Joo Chae, Ahwon Lee, Yoon Jin Cha, Jieun Lee, Sung Gwe Ahn, Jun Kang
Scientific Reports.2024;[Epub] CrossRef
Evaluating the Clinico-Pathological Relationship Between Stromal Tumor-Infiltrating Lymphocytes and Androgen Receptor Expression Across Molecular Subtypes of Invasive Breast Carcinoma
Adil Aziz Khan, Sana Ahuja, Kiruthikasri G., Sufian Zaheer
Indian Journal of Surgical Oncology.2024; 15(4): 802. CrossRef
Biomarkers and translational research approaches in breast cancer—an update
Angelika M. Starzer, Anna S. Berghoff, Rupert Bartsch
memo - Magazine of European Medical Oncology.2023; 16(1): 42. CrossRef
Evaluation of predictive and prognostic value of androgen receptor expression in breast cancer subtypes treated with neoadjuvant chemotherapy
Zhendong Shi, Yingxue Liu, Shichao Zhang, Shuanglong Cai, Xu Liu, Jie Meng, Jin Zhang
Discover Oncology.2023;[Epub] CrossRef

6,711 View
183 Download
8 Web of Science
7 Crossref

Impacts of Subtype on Clinical Feature and Outcome of Male Breast Cancer: Multicenter Study in Korea (KCSG BR16-09): Jieun Lee, Keun Seok Lee, Sung Hoon Sim, Heejung Chae, Joohyuk Sohn, Gun Min Kim, Kyung-Hee Lee, Su Hwan Kang, Kyung Hae Jung, Jae-ho Jeong, Jae Ho Byun, Su-Jin Koh, Kyoung Eun Lee, Seungtaek Lim, Hee Jun Kim, Hye Sung Won, Hyung Soon Park, Guk Jin Lee, Soojung Hong, Sun Kyung Baek, Soon Il Lee, Moon Young Choi, In Sook Woo; Cancer Res Treat. 2023;55(1):123-135. Published online March 24, 2022; DOI: https://doi.org/10.4143/crt.2021.1561

Abstract PDF Supplementary Material PubReader ePub

Purpose
The treatment of male breast cancer (MBC) has been extrapolated from female breast cancer (FBC) because of its rarity despite their different clinicopathologic characteristics. We aimed to investigate the distribution of intrinsic subtypes based on immunohistochemistry, their clinical impact, and treatment pattern in clinical practice through a multicenter study in Korea.
Materials and Methods
We retrospectively analyzed clinical data of 248 MBC patients from 18 institutions across the country from January 1995 to July 2016.
Results
The median age of MBC patients was 63 years (range, 25 to 102 years). Among 148 intrinsic subtype classified patients, 61 (41.2%), 44 (29.7%), 29 (19.5%), and 14 (9.5%) were luminal A, luminal B, human epidermal growth factor receptor 2, and triple-negative breast cancer, respectively. Luminal A subtype showed trends for superior survival compared to other subtypes. Most hormone receptor-positive patients (166 patients, 82.6%) received adjuvant endocrine treatment. Five-year completion of adjuvant endocrine treatment was associated with superior disease-free survival (DFS) in patients classified with an intrinsic subtype (hazard ratio [HR], 0.15; 95% confidence interval [CI], 0.04 to 0.49; p=0.002) and in all patients (HR, 0.16; 95% CI, 0.05 to 0.54; p=0.003).
Conclusion
Distribution of subtypes of MBC was similar to FBC and luminal type A was most common. Overall survival tended to be improved for luminal A subtype, although there was no statistical significance. Completion of adjuvant endocrine treatment was associated with prolonged DFS in intrinsic subtype classified patients. MBC patients tended to receive less treatment. MBC patients should receive standard treatment according to guidelines as FBC patients.

Citations

Citations to this article as recorded by

HER2 expression and pathway status in male breast cancer patients: results of an integrated analysis among 6,150 patients
Boqiang Lyu, Shidi Zhao, Hui Wang, Shouping Gong, Biyuan Wang
Scientific Reports.2025;[Epub] CrossRef
Male breast cancer - a single center experience
Igor Djurisic, Milan Zegarac, Milan Kocic, Vladimir Jokic, Nikola Vucic, Ognjen Petrovic, Nada Santrac, Jovana Koncar, Andjela Ivezic, Srdjan Nikolic
Srpski arhiv za celokupno lekarstvo.2025; 153(1-2): 53. CrossRef
Clinicopathologic Features and Prognoses of Male Patients With Breast Cancer
Meiling Huang, Jingjing Xiao, Changjiao Yan, Rui Ling, Ting Wang
American Journal of Men's Health.2024;[Epub] CrossRef

7,572 View
188 Download
4 Web of Science
3 Crossref

Sarcoma

Clinicopathologic Characteristics and Clinical Outcome of Localized Liposarcoma: A Single-Center Experience over 25 Years and Evaluation of PD-L1 Expression: Heejung Chae, Jeong Eun Kim, Wanlim Kim, Jong-Seok Lee, Si Yeol Song, Min Hee Lee, Hye Won Chung, Kyung-Ja Cho, Joon Seon Song, Jin-Hee Ahn; Cancer Res Treat. 2022;54(2):579-589. Published online July 6, 2021; DOI: https://doi.org/10.4143/crt.2021.496

Abstract PDF Supplementary Material PubReader ePub

Purpose
For liposarcoma (LPS), clinical course and proper treatment strategies have not been well-established. Recently, immune-checkpoint inhibitors have shown potential efficacy in LPS. We aimed to describe the clinical course of LPS and evaluate the clinical impact of programmed death-ligand 1 (PD-L1).
Materials and Methods
We reviewed all consecutive patients (n=332) who underwent curative-intent surgery for localized LPS at Asan Medical Center between 1989 and 2017. PD-L1 testing was performed in well-differentiated and dedifferentiated LPS.
Results
The median age was 56 years with males comprising 60.8%. Abdomen-pelvis (47.6%) and well-differentiated (37.7%) were the most frequent primary site and histologic subtype, respectively. During a median follow-up of 81.2 months, recurrence was observed in 135 (40.7%), and 86.7% (117/135) were loco-regional. Well-differentiated subtype (hazard ratio [HR], 0.38), abdomen-pelvis origin (HR, 2.43), tumor size larger than 5 cm (HR, 1.83), positive resection margin (HR, 2.58), and postoperative radiotherapy (HR, 0.36) were significantly related with recurrence-free survival as well as visceral involvement (HR, 1.84) and multifocality (HR, 3.79) in abdomen-pelvis LPS. PD-L1 was positive in 31.5% (23/73) and 51.3% (39/76) of well-differentiated and dedifferentiated LPS, respectively, but had no impact on survival outcomes.
Conclusion
Clinical course of LPS was heterogeneous according to histology and anatomic location. Clear resection margin was important to lower recurrence and postoperative radiotherapy might have additional benefit. A decent portion of well-differentiated and dedifferentiated LPS were positive for PD-L1, but its prognostic role was unclear. Further research is needed to determine clinical implications of PD-L1, especially for advanced-stage LPS with unmet needs for effective systemic treatment.

Citations

Citations to this article as recorded by

Recurrent Intrathoracic Liposarcoma: A Case Report and a Comprehensive Literature Review of a Rare Clinical Entity
Vasileios Leivaditis , Manfred Dahm , Athanasios Papatriantafyllou, Hans-Georg Keul, Lydia Kohl, Hans-Joachim Schäfers
Cureus.2024;[Epub] CrossRef
Clinicopathological Features of Intrathoracic Liposarcoma—A Systematic Review with an Illustrative Case
Kajetan Kiełbowski, Nikola Ruszel, Seweryn Adam Skrzyniarz, Małgorzata Edyta Wojtyś, Rafał Becht, Konrad Ptaszyński, Darko Gajić, Janusz Wójcik
Journal of Clinical Medicine.2022; 11(24): 7353. CrossRef

7,448 View
119 Download
1 Web of Science
2 Crossref

Gastrointestinal cancer

Trends in Chemotherapy Patterns and Survival of Patients with Advanced Gastric Cancer over a 16-Year Period: Impact of Anti-HER2–Targeted Agent in the Real-World Setting: Dong-Hoe Koo, Min-Hee Ryu, Mi-Yeon Lee, Heejung Chae, Eo Jin Kim, Mee-Sun Moon, Yoon-Koo Kang; Cancer Res Treat. 2021;53(2):436-444. Published online October 6, 2020; DOI: https://doi.org/10.4143/crt.2020.725

Abstract PDF Supplementary Material PubReader ePub

Purpose
This study aimed to evaluate the survivals of patients with metastatic or recurrent gastric cancer (MRGC) over a period of 16 years and to investigate the recent changes in chemotherapy patterns.
Materials and Methods
A total of 5,384 patients who received chemotherapy for MRGC between 2000 and 2015 were analyzed. The analysis focused on a comparison of the first-line chemotherapy between four periods: 2000–2003 (period 1), 2004–2007 (period 2), 2008–2011 (period 3), and 2012–2015 (period 4).
Results
There were 880 patients (16%) in period 1, 1,573 (29%) in period 2, 1,435 (27%) in period 3, and 1,496 (28%) in period 4. Cytotoxic doublet-based therapy was the most commonly used (78%) first-line chemotherapy, and the combination of trastuzumab and doublet chemotherapy was provided to 288 patients. The OS rates at 12 and 24 months were steadily improved as follows: 39.2% and 14.6% in period 1, 43.5% and 17.6% in period 2, 50.3% and 20.6% in period 3, and 51.7% and 24.1% in period 4, respectively (p < 0.001). Among the patients who received the doublet-based chemotherapy, the median OS of those who received trastuzumab was 18.0 months (95% CI, 15.5–20.6), while that of those who received other doublet therapies was 11.2 months (95% CI, 10.8–11.6).
Conclusion
The OS was improved over time with advancements in chemotherapy, particularly the introduction of the anti-HER2–targeted agent, which contributed to the increase in the number of long-term survivors and established the superiority of OS for the treatment of MRGC.

Citations

Citations to this article as recorded by

Treatment Modalities and Survival Outcomes in Gastric Cancer: Insights From Najran, Saudi Arabia
Ahmed M Badheeb, Ibrahim A Alyami, Ahlam Y Alyami, Mohammed Alyami, Mugahed Al Walani, Samer Alkarak, Abdelaziz A Aman, Fahad M Albaiji, Ali G Al Masad, Abdullah S Alyami, Islam A Seada, Abdullah Abu Bakar
Cureus.2025;[Epub] CrossRef
Treatment patterns and outcomes in advanced or metastatic gastric/gastroesophageal junction adenocarcinoma in China
Jingdong Zhang, Guangyu Wang, Xianhe Xie, Wensheng Pan, Qian Dong, Nianhai Zhang, Jie Dong, Li Zhou, Chan Zhou, Jinnan Li, Grace Segall, Yanqiao Zhang
Future Oncology.2025; 21(10): 1179. CrossRef
Factors associated with the efficacy of first-line nivolumab plus chemotherapy in advanced gastric cancer patients with deficient mismatch repair
Young-Gyu Park, Hyung-Don Kim, Jaewon Hyung, Young Soo Park, Min-Hee Ryu
Gastric Cancer.2024; 27(4): 840. CrossRef
Varlitinib and Paclitaxel for EGFR/HER2 Co-expressing Advanced Gastric Cancer: A Multicenter Phase Ib/II Study (K-MASTER-13)
Dong-Hoe Koo, Minkyu Jung, Yeul Hong Kim, Hei-Cheul Jeung, Dae Young Zang, Woo Kyun Bae, Hyunki Kim, Hyo Song Kim, Choong-kun Lee, Woo Sun Kwon, Hyun Cheol Chung, Sun Young Rha
Cancer Research and Treatment.2024; 56(4): 1136. CrossRef
Breakthroughs in the Systemic Treatment of HER2-Positive Advanced/Metastatic Gastric Cancer: From Singlet Chemotherapy to Triple Combination
Sun Young Rha, Hyun Cheol Chung
Journal of Gastric Cancer.2023;[Epub] CrossRef
Association between HER2 heterogeneity and clinical outcomes of HER2-positive gastric cancer patients treated with trastuzumab
Kyunghye Bang, Jaekyung Cheon, Young Soo Park, Hyung-Don Kim, Min-Hee Ryu, Yangsoon Park, Meesun Moon, Hyungeun Lee, Yoon-Koo Kang
Gastric Cancer.2022; 25(4): 794. CrossRef
Clinicopathological features and CT findings of papillary gastric adenocarcinoma
Mengying Xu, Song Liu, Xiangmei Qiao, Lin Li, Changfeng Ji, Zhengyang Zhou
Abdominal Radiology.2022; 47(11): 3698. CrossRef
New prognostic model for patients with advanced gastric cancer: Fluoropyrimidine/platinum doublet for first-line chemotherapy
Dong-Hoe Koo, Min-Hee Ryu, Mi-Yeon Lee, Mee-Sun Moon, Yoon-Koo Kang
World Journal of Gastroenterology.2021; 27(48): 8357. CrossRef

8,021 View
165 Download
8 Crossref

First
Prev
Page of 1
Next
Last

Search